•$Eledon Pharmaceuticals (ELDN.US)$+7.7% (topline results from phase 2a trial of tegoprubart demonstrating safety target engagement and biomarker response in patients living with amyotrophic lateral sclerosis)
•$Swvl Holdings (SWVL.US)$+4.9% (announces portfolio optimization program to turn cash flow positive in 2023)
•$Takeda Pharmaceutical (TAK.US)$-1.2% (Moderns and Takeda (TAK) announce plans to transfer Marketing Authorization for Spikevax COVID-19 vaccine in Japan to Moderna).